Abstract
Pharmacokinetics and metabolism of droloxifene, a new antiestrogenic drug, have been investigated by single- and multiple-dose studies in postmenopausal patients with advanced breast cancer. Short terminal elimination half-life, low accumulation, and improved drug tolerability are the most striking features of this safe and effective new antiestrogen. Bioequivalence of film-coated tablet, tablet, and standard solution of droloxifene has been shown. The concentrations of droloxifene and its metabolites have been determined by a highly selective HPLC method.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Administration, Oral
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / metabolism
-
Antineoplastic Agents / pharmacokinetics*
-
Biological Availability
-
Breast Neoplasms / metabolism*
-
Chromatography, High Pressure Liquid
-
Drug Evaluation
-
Estrogen Antagonists / metabolism
-
Estrogen Antagonists / pharmacokinetics*
-
Female
-
Half-Life
-
Humans
-
Middle Aged
-
Tamoxifen / analogs & derivatives*
-
Tamoxifen / metabolism
-
Tamoxifen / pharmacokinetics
Substances
-
Antineoplastic Agents
-
Estrogen Antagonists
-
Tamoxifen
-
droloxifene